A review on camelid nanobodies with potential application in veterinary medicine
- PMID: 38869749
- DOI: 10.1007/s11259-024-10432-x
A review on camelid nanobodies with potential application in veterinary medicine
Abstract
The single variable domains of camelid heavy-chain only antibodies, known as nanobodies, have taken a long journey since their discovery in 1989 until the first nanobody-based drug's entrance to the market in 2022. On account of their unique properties, nanobodies have been successfully used for diagnosis and therapy against various diseases or conditions. Although research on the application of recombinant antibodies has focused on human medicine, the development of nanobodies has paved the way for incorporating recombinant antibody production in favour of veterinary medicine. Currently, despite many efforts in developing these biomolecules with diversified applications, significant opportunities exist for exploiting these highly versatile and cost-effective antibodies in veterinary medicine. The present study attempts to identify existing gaps and shed light on paths for future research by presenting an updated review on camelid nanobodies with potential applications in veterinary medicine.
Keywords: Antibodies; Heavy-chain only; Low-cost; Recombinant; Single variable domains; Versatile.
© 2024. The Author(s), under exclusive licence to Springer Nature B.V.
Similar articles
-
Nanobodies derived from Camelids represent versatile biomolecules for biomedical applications.Biomater Sci. 2020 Jul 7;8(13):3559-3573. doi: 10.1039/d0bm00574f. Epub 2020 Jun 3. Biomater Sci. 2020. PMID: 32490444 Review.
-
Applications of Nanobodies.Annu Rev Anim Biosci. 2021 Feb 16;9:401-421. doi: 10.1146/annurev-animal-021419-083831. Epub 2020 Nov 24. Annu Rev Anim Biosci. 2021. PMID: 33233943 Review.
-
[Application of nanobody in cancer treatment].Sheng Wu Gong Cheng Xue Bao. 2017 Jul 25;33(7):1085-1090. doi: 10.13345/j.cjb.160491. Sheng Wu Gong Cheng Xue Bao. 2017. PMID: 28869728 Review. Chinese.
-
Nanobody-based heavy chain antibodies and chimeric antibodies.Immunol Rev. 2024 Nov;328(1):466-472. doi: 10.1111/imr.13385. Epub 2024 Aug 30. Immunol Rev. 2024. PMID: 39212236 Free PMC article. Review.
-
Identification of Useful Nanobodies by Phage Display of Immune Single Domain Libraries Derived from Camelid Heavy Chain Antibodies.Curr Pharm Des. 2016;22(43):6500-6518. doi: 10.2174/1381612822666160923114417. Curr Pharm Des. 2016. PMID: 27669966 Review.
References
-
- Abbady AQ, Al-Mariri A, Zarkawi M, Al-Assad A, Muyldermans S (2011) Evaluation of a nanobody phage display library constructed from a Brucella-immunised camel. Vet Immunol Immunopathol 142(1–2):49–56. https://doi.org/10.1016/j.vetimm.2011.04.004 - DOI - PubMed
-
- Abeijon C, Dilo J, Tremblay JM, Viana AG, Bueno LL, Carvalho SF, Fujiwara RT, Shoemaker CB, Campos-Neto A (2018) Use of VHH antibodies for the development of antigen detection test for visceral leishmaniasis. Parasite Immunol 40(11):e12584. https://doi.org/10.1111/pim.12584 - DOI - PubMed - PMC
-
- Arbabi-Ghahroudi M (2022) Camelid single-domain antibodies: promises and challenges as lifesaving treatments. Int J Mol Sci 23(9):5009. https://doi.org/10.3390/ijms23095009 - DOI - PubMed - PMC
-
- Arce LP, Pavan MF, Bok M, Gutiérrez SE, Estein SM, Santos AT, Condorí WE, Uhart MM, Parreño V, Vizoso-Pinto MG, Ibañez LI (2023) A multispecies competitive nanobody-based ELISA for the detection of antibodies against hepatitis E virus. Sci Rep 13(1):15448. https://doi.org/10.1038/s41598-023-41955-z - DOI - PubMed - PMC
-
- Ardekani LS, Gargari SLM, Rasooli I, Bazl MR, Mohammadi M, Ebrahimizadeh W, Bakherad H, Zare H (2013) A novel nanobody against urease activity of Helicobacter pylori. Int J Infect Dis 17(9):e723–e728. https://doi.org/10.1016/j.ijid.2013.02.015 - DOI - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources